Indications for Triptans
Triptans are indicated for the acute treatment of moderate to severe episodic migraine headache (1-14 headache days per month) in nonpregnant adults, and should be added to NSAIDs or acetaminophen when these medications alone fail to provide adequate pain relief. 1
Primary Indication
Triptans are migraine-specific medications approved for:
- Acute episodic migraine (moderate to severe intensity) in outpatient settings
- Cluster headache attacks 2
The 2025 American College of Physicians guideline establishes a clear treatment algorithm: Start with NSAIDs or acetaminophen at adequate doses, then add a triptan if monotherapy fails 1.
Specific Clinical Scenarios
When to Add Triptans
Add a triptan to an NSAID when patients with moderate to severe migraine do not respond adequately to NSAID monotherapy (strong recommendation, moderate-certainty evidence) 1.
Add a triptan to acetaminophen when NSAIDs are contraindicated or not tolerated and acetaminophen alone is insufficient (conditional recommendation, low-certainty evidence) 1.
The combination of sumatriptan plus naproxen demonstrates the greatest net benefit among all acute migraine treatments, with 110 more patients per 1000 achieving pain freedom at 2 hours compared to NSAID monotherapy 1.
Severe Presentations
Use nonoral triptans (subcutaneous, nasal spray) with antiemetics for patients experiencing severe nausea or vomiting 1. Subcutaneous sumatriptan 6 mg has the fastest onset, with 90.6% of 2-hour pain-free patients achieving this by 4 hours 3.
Available Triptans
Seven triptans are available with multiple formulations 1:
- Almotriptan
- Eletriptan
- Frovatriptan
- Naratriptan
- Rizatriptan
- Sumatriptan (oral, subcutaneous, nasal spray)
- Zolmitriptan
Rizatriptan 10 mg, eletriptan 80 mg, and almotriptan 12.5 mg provide the highest likelihood of consistent success across multiple attacks 4.
Critical Contraindications
Do not prescribe triptans to patients with:
- Coronary artery disease or cerebrovascular disease 4, 5
- Cardiac arrhythmias 6
- Pregnancy or lactation 1
All triptans cause 10-20% coronary artery vasoconstriction at clinical doses 5. Despite this, 13.9% of patients prescribed triptans have at least one contraindication, with cardiac arrhythmia being most common (8.4%) 6.
Treatment Timing and Frequency
Counsel patients to treat early when pain is mild to maximize pain-free response and minimize adverse events 5. The combination therapy approach increases efficacy: 180 more patients per 1000 achieve sustained pain relief up to 48 hours with triptan-NSAID combination versus NSAID alone 1.
Medication Overuse Warning
Limit triptan use to fewer than 10 days per month to prevent medication overuse headache, defined as headache occurring ≥15 days per month for ≥3 months due to acute medication overuse 1, 7.
When Triptans Are NOT Indicated
- Mild episodic migraine: Use NSAID or acetaminophen monotherapy 1
- Migraine prevention: Triptans are abortive medications, not preventive 2
- Indomethacin-responsive headaches: Triptans fail in chronic paroxysmal hemicrania and hemicrania continua 2
Never use opioids or butalbital for acute episodic migraine 1.
Second-Line Alternatives
If patients fail combination therapy with triptan plus NSAID/acetaminophen, consider 1:
- CGRP antagonists (gepants: rimegepant, ubrogepant, zavegepant)
- Ergot alkaloids (dihydroergotamine)
- Lasmiditan (ditan) as last resort
These alternatives cost significantly more (CGRP antagonists: $5,994 annually vs. triptan combinations: ~$500) 1.